Overview
The findings suggest that distinguishing between these subtypes can improve treatment strategies, such as using PD-1 inhibitors for mutational types and exploring organ preservation for early-stage cases.
Research from Memorial Sloan Kettering (MSK) between 2022 and 2023 reveals that mismatch repair deficient (MMRd) endometrial cancer is heterogeneous, with prognosis and immunotherapy response driven by whether the deficiency is caused by genetic mutations (better prognosis) or epigenetic silencing (worse prognosis). The findings suggest that distinguishing between these subtypes can improve treatment strategies, such as using PD-1 inhibitors for mutational types and exploring organ preservation for early-stage cases.